The effects of N-linked-oligosaccharide-processing inhibitors on the fusion of rat L6 myoblasts to form myotubes were examined. The glucosidase inhibitor N-methyl-I -deoxynojirimycin (MDJN) greatly inhibited fusion, whereas the mannosidase inhibitor 1-deoxymannojirimycin (ManDJN) had relatively little effect, although both compounds prevented the formation of N-linked complex oligosaccharides. These results indicate that complex oligosaccharides on glycoproteins do not play a role in myoblast fusion. With MDJN, high-mannose oligosaccharides containing three glucose residues and seven to eight mannose residues were found at the cell surface, whereas with ManDJN, non-glucosylated high-mannose oligosaccharides with seven to nine mannose residues were obtained. These results indicate that the persistence of glucose residues on high-mannose oligosaccharides may be responsible for the inhibition of fusion. It is suggested that glucose either masks the cell-surface recognition process leading to fusion or prevents the cell-surface expression of specific glycoprotein(s) essential to the fusion process.
INTRODUCTION
During the terminal differentiation of skeletal muscle, mononucleate myoblasts fuse to form myotubes. These elongate, multinucleate, cells subsequently differentiate further to form striated muscle fibres. The precise sequence of events controlling the process of myoblast fusion, and the molecular components of the membrane involved in the fusion process, are not yet understood. Studies on the formation of myoblast aggregates in suspension suggest that fusion is-a-multi-step process,* with discrete stages of myoblast recognition, adhesion and membrane union, each involving different or additional molecules (Knudsen & Horwitz, 1977) . Several studies have shown that there are alterations in cell-surface glycoproteins (Marino et al., 1980; Wahrmann etral., 1980; Walsh & Phillips, 1981; Boitani et al., 1982; Cates et al., 1984a,b; Holland et al., 1984) coincident with myoblast fusion, and it has been suggested that glycoproteins are involved in the adhesion stage preceding fusion (Knudsen, 1985) . There is no direct evidence that any specific glycoproteins play an essential role in the fusion process. There are indications, however, that glycoproteins containing asparagine-linked (N-linked) oligosaccharides may be causally involved in myoblast fusion. Fusion is blocked in concanavalin A-resistant mutants of L. myoblasts (Parfett et al., 1983; Cates et al., 1984a) . Furthermore, tunicamycin, which interferes with the synthesis of dolichyl pyrophosphate oligosaccharides required for the formation of all N-linked oligosaccharides, greatly inhibits myoblast fusion (Gilfix & Sanwal, 1980; Olden et al., 1981) .
N-Linked oligosaccharides are present on glycoproteins in two major forms, namely complex and high mannose, which both arise from processing of the same precursor oligosaccharide, Glc3Man9GlcNAc2. The initial steps in this processing are the removal of the glucose residues by two specific rough-endoplasmic-reticulum a-glucosidases, followed by removal of a variable number of mannose residues by rough-endoplasmic-reticulum and Golgi a-mannosidases. In the case ofcomplex oligosaccharides, terminal glycosylation by specific glycosyltransferases subsequently .-occurs, in the (Golgi.. [for. a review, see Kornfeld & Kornfeld (1985) ]. Since tunicamycin inhibits the synthesis of all N-linked oligosaccharides, its use does not give any information regarding the possible preferential involvement ofthe different types ofN-linked oligosaccharides in the fusion process. Furthermore, the complete inhibition obtained with tunicamycin may result in increased proteolytic degradation of the non-glycosylated proteins (Olden et al., 1981) . Recent studies indicate that compounds which interfere with different stages in oligosaccharide processing can be used to modify the structure of N-linked oligosaccharides on glycoproteins [for a review, see Schwarz & Datema (1984) ]. We have shown that the glucose analogue DJN -is a potent inhibitor of processing a-glucosidases I and II and that it is active in intact cells (Saunier et al., 1982) . It has since been found that its derivative, MDJN, is a more useful inhibitor of the glucosidases (Romero et al., 1983 (Romero et al., , 1985a Hettkamp et al., 1984) and that the corresponding mannose analogue, ManDJN, inhibits processing Golgi a-mannosidase I (Bischoff & Kornfeld, 1984; Fuhrmann et al., 1984; Romero et al., 1985c) .
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Since MDJN and ManDJN prevent the formation of complex N-linked oligosaccharides, they can be used to investigate the relative function of high-mannose and complex oligosaccharides in biological processes. In the present study we examined the effects of these processing inhibitors on the fusion of L6 rat myoblasts and on the synthesis of N-linked oligosaccharides in these cells. It was found that MDJN prevents myoblast fusion, whereas ManDJN has relatively little effect on fusion.
MATERIALS AND METHODS Materials L6 myoblasts were obtained through the courtesy ofDr. B. D. Sanwal, University of Western Ontario, London, Ontario, Canada; these were a subclone, L6-9 (Ball et al., 1979) of the line originally isolated by Yaffe (1968 (Kilker et al., 1981) .
Estimation of fusion of L6 myoblast cells
The cells were seeded at a concentration of 104 cells/ml in triplicate in 24-well dishes in 0.5 ml of DMEM containing 10% (v/v) horse serum and either MDJN or ManDJN, as indicated. After 7 days in culture the cells were fixed with 2.5% glutaraldehyde and were stained with haematoxylin and eosin. The nuclei were counted in ten random fields at 400 x magnification and the percentage of the total nuclei in myotubes was determined. Only cells containing at least three nuclei were counted as myotubes. Labelling of cells L6 rat myoblast cells, plated in duplicate 100 mmdiameter dishes at a density of 3 x 105 cells, were cultured in 10 ml of DMEM containing 1 g of glucose/l, 500 (v/v) fetal-calf serum and 500 horse serum. When present, the inhibitors MDJN and ManDJN were added at the time of seeding to yield a final concentration of 2 mm. After cells had spent 3 days in culture, 10 ml of fresh medium containing D-[2-3H]mannose at a concentration of 15 1tCi/ml were added with or without inhibitor. After 24 h of labelling the cells were washed three times with 10 ml of Dulbecco's phosphate-buffered saline, pH 7.4. The cells were then exposed to 3 ml ofO. 10 trypsin/0.05 00 EDTA in phosphate-buffered saline for 10 min at room temperature. After trypsin treatment the suspension was centrifuged at 800 g for 5 min to remove any detached cells and the supernatant was freeze-dried. This material, which is enriched in cell-surface components, is subsequently referred to as the 'cell-surface-glycopeptide fraction'.
Fractionation of glycopeptides and oligosaccharides
The cell-surface glycopeptides were exhaustively digested for 24 h at 60°C in 1 ml ofTris/HCl buffer, pH 8.0, containing 1 mM-CaCl2, 2 mg of Pronase/ml and 25 ,tg each of cycloheximide and chloramphenicol/ml. The glycopeptides were chromatographed on a column (1 cm x 100 cm) ofBio-Gel P-6 in 0.1 M-pyridine/acetate/ 0.5 mM-NaN3, pH 5.0, with BSA (to determine the void volume) and mannose. Fractions (1 ml) were collected and assayed for radioactivity. The phenol/H2SO4 reaction was used to locate mannose, and A280 to locate BSA. The glycopeptide fractions were pooled, freeze-dried and treated for 24 h with 2 munits of endo-H in 200 ,ul of 0.1 M-sodium citrate, pH 5.5, containing 25 ,ug each of cycloheximide and chloramphenicol/ml. The products obtained were chromatographed on the same column of Bio-Gel P-6 as that described above. The endo-H-sensitive oligosaccharides were pooled, concentrated, and chromatographed with 14C-labelled oligosaccharide standards on a column (25 cm x 0.46 cm) of 5 ,umparticle-size Aminospherisorb (Phase Separations; packed by Chromatography Sciences Co., Ville Mont Royal, Quebec, Canada) with a Varian model 5000 liquid chromatograph (Romero et al., 1985a The endo-H-released oligosaccharides obtained from the Bio-Gel P-6 column were freeze-dried and then incubated for 72 h at 37°C in 200 ,ul of 50 mM-sodium acetate buffer, pH 5.0, containing 100 mM-NaCl, 0.1 mMZnSO4 and 0.02% NaN3. Jack-bean a-mannosidase (2 units) was added at 0, 24 h and 48 h of incubation. After 72 h of incubation the samples were boiled for 3 min, centrifuged, and the supernatants were desalted through coupled columns of AG 50 W (X8, H+ form, 200-400 mesh) and AGI (X8, formate form, 200-400 mesh) resins. The a-mannosidase treatment was repeated and the samples were subjected to h.p.l.c. as described above (Romero et al., 1985a) .
RESULTS

Effects of MDJN and ManDJN on myoblast fusion
When rat L6 myoblast cells were subcultured, they first went through a period of rapid growth until they reached confluence after about 4 days in culture. Fusion of myoblasts to form myotubes usually began on day 4 of culture, and reached a maximum after about 6-7 days.
On day 7, about 750% of the nuclei were found in myotubes. Addition of MDJN at the time of seeding greatly inhibited fusion, so that only 230% of the nuclei were found in myotubes after 7 days in culture. In contrast, the addition of ManDJN under the same conditions only had a small inhibitory effect on fusion, and about 60 % of the nuclei were recovered in myotubes ( Figs. 1 and 2 ). Addition of MDJN 1 and 2 days after seeding still greatly inhibited fusion, but this inhibition became less and less pronounced with delayed addition of Time of addition of inhibitor (days after plating) Fig. 1 this compound. Addition of MDJN 4 days after seeding had little effect on the ability of the cells to form myotubes. The inhibitory effect of MDJN was concentration-dependent, with a maximum inhibition observed at a concentration of 0.5 mm (Fig. 3) . Castanospermine, another glucosidase inhibitor (Pan et al., 1983) , also inhibited fusion; at concentrations of 10, 50 and 100 jug/ml, about 60, 47 and 43% of the nuclei respectively were associated with myotubes after 7 days in culture. The simultaneous addition of leupeptin (25-100 ug/ml), which had been shown previously to reverse the effect of tunicamycin (Olden et al., 1981) (Fig.  4d) . In the MDJN-treated cells, the cell-surface glycopeptides consisted ofa major fraction (Ka. = 0.35) with a poorly resolved shoulder eluted earlier (Fig. 4b) . After endo-H treatment (Fig. 4e) mannose oligosaccharides as described previously (Romero et al., 1985a) . The endo-H-sensitive oligosaccharides obtained from control cells were resolved into five oligosaccharides, which were eluted earlier than the glucosylated standards and corresponded, in their elution position, to Man5_GlcNAc oligosaccharides (Fig. 5a) . None of these oligosaccharide fractions contained glucose residues, since all the radioactivity was eluted with mannose after jack-bean a-mannosidase treatment (Fig. 5d) . The endo-H-sensitive oligosaccharides obtained from MDJN-treated cells consisted of two major fractions with R = 0.89 and 0.79 (Fig. Sb) . After treatment of the mixture with jack-bean a-mannosidase, only 45% of the radioactivity was eluted with mannose, and about 45% of the radioactivity was recovered in an oligosaccharide with R = 0.42 (Fig. 5e ). This elution position corresponded to the elution of the oligosaccharide obtained by a similar treatment of standard glucose-labelled Glc3Man,GlcNAc with jack-bean amannosidase. These results demonstrate that the two major oligosaccharides formed in the presence of MDJN contain three glucose residues and, from their relative elution position (Romero et al., 1985a) , consist of Glc3Man7GlcNAc and Glc3Man8GlcNAc; there was also a trace of Glc3Man,GlcNAc present (Fig. 5b) . In ManDJN-treated cells the major oligosaccharides correspond, in their elution position, to Man7,9GlcNAc (Fig. Sc) ; these are not glucosylated, since all the radioactivity was eluted with mannose after treatment with jack-bean a-mannosidase (Fig. Sf) .
To ensure that the inhibition of fusion by MDJN was not due to an effect of the inhibitor on the synthesis of the dolichyl pyrophosphate oligosaccharide precursor, the lipid-linked oligosaccharides formed during a 2 h pulse-labelling with [2-3H]mannose were examined by h.p.l.c. as described by Romero et al. (1985b) after 3 days in culture. The synthesis ofGlc3Man9GlcNAc2, the major oligosaccharide product, was not affected by MDJN (results not shown).
DISCUSSION
The present results demonstrate that fusion of L6 rat myoblasts in culture is greatly inhibited by MDJN, but is not significantly affected by ManDJN. Since both compounds were shown to prevent the synthesis of N-linked complex oligosaccharides in these cells, the results indicate that complex oligosaccharides do not play a role in myoblast fusion. In fact, as observed previously in other cells (Romero et al., 1985a,c) The present observations indicate that the persistence of glucose residues on high-mannose oligosaccharides may be responsible for the inhibition of fusion observed with MDJN. The fact that castanospermine, another processing inhibitor with a mode of action similar to that of MDJN (Pan et al., 1983) , also inhibits fusion further supports this concept. Two possible explanations for this effect of glucose can be envisaged. It may be that high-mannose oligosaccharides on one or more glycoproteins at the cell surface are intimately involved in the recognition process leading to adhesion and fusion of the myoblasts; in this case the presence ofglucose residues on these oligosaccharides would directly mask this recognition. The other possibility is that the protein domain of specific cell-surface glycoprotein(s) is essential for recognition, and that the persistence of glucose residues on the specific glycoprotein(s) may prevent their appearance at the cell surface. Olden et al. (1981) previously reported that inhibition of fusion with tunicamycin was reversed by the proteinase inhibitor leupeptin; although this observation was not confirmed (Cates et al., 1984b) , this reversal indicated that the carbohydrate groups are not directly involved in the process of fusion. Since, in the present work, leupeptin had no effect on the inhibition of fusion observed in the presence of MDJN, it is unlikely that the effect of MDJN results from increased proteolytic degradation of glycoproteins essential in the fusion process. It has been shown previously that DJN treatment can interfere with the translocation from rough endoplasmic reticulum to Golgi and with the secretion of some glycoproteins, and not of others (Gross et al., 1983; Peyrieras et al., 1983; Lodish & Kong, 1984) . More recently, it was found that both MDJN and castanospermine prevent the cell-surface expression of the v-fms-oncogene-encoded glycoprotein, thereby reversing the 'in vitro' tumour phenotype (Nichols et al., 1985) . These results indicate that preventing glucose removal from certain glycoproteins interferes with their subsequent translocation to the Golgi and therefore to the cell surface. The possibility must be considered, therefore, that the glycoprotein(s) involved in fusion are not properly targetted to the cell surface in the presence of MDJN but are normally inserted into the membrane in the presence of ManDJN.
